ACC 100 MG kihisev tablett Eesti - eesti - Ravimiamet

acc 100 mg kihisev tablett

sandoz pharmaceuticals d.d. - atsetüültsüsteiin - kihisev tablett - 100mg 20tk

MUCOVIT kihisev tablett Eesti - eesti - Ravimiamet

mucovit kihisev tablett

pharmaestica manufacturing oÜ - atsetüültsüsteiin - kihisev tablett - 200mg 10tk; 200mg 20tk

ACC 100 MG suukaudse lahuse pulber Eesti - eesti - Ravimiamet

acc 100 mg suukaudse lahuse pulber

sandoz pharmaceuticals d.d. - atsetüültsüsteiin - suukaudse lahuse pulber - 100mg 1annus 20tk

BRONCHOSTAD kihisev tablett Eesti - eesti - Ravimiamet

bronchostad kihisev tablett

stada arzneimittel ag - atsetüültsüsteiin - kihisev tablett - 600mg 20tk; 600mg 10tk

ACC HOT 200MG suukaudse lahuse pulber Eesti - eesti - Ravimiamet

acc hot 200mg suukaudse lahuse pulber

sandoz pharmaceuticals d.d. - atsetüültsüsteiin - suukaudse lahuse pulber - 200mg 1annus 20tk

ACC 200 MG kihisev tablett Eesti - eesti - Ravimiamet

acc 200 mg kihisev tablett

sandoz pharmaceuticals d.d. - atsetüültsüsteiin - kihisev tablett - 200mg 20tk

ACC suukaudne lahus Eesti - eesti - Ravimiamet

acc suukaudne lahus

sandoz pharmaceuticals d.d. - atsetüültsüsteiin - suukaudne lahus - 20mg 1ml 200ml 1tk

WINTROZEN kihisev tablett Eesti - eesti - Ravimiamet

wintrozen kihisev tablett

zentiva k.s. - atsetüültsüsteiin - kihisev tablett - 600mg 20tk

Clopidogrel Acino Euroopa Liit - eesti - EMA (European Medicines Agency)

clopidogrel acino

acino ag - klopidogreel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitrombootilised ained - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.

Clopidogrel Viatris (previously Clopidogrel Taw Pharma) Euroopa Liit - eesti - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - klopidogreel-besilaat - peripheral vascular diseases; stroke; myocardial infarction - antitrombootilised ained - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st segmendi elevatsiooniga ägeda müokardi infarkti korral kombinatsioonis asa on meditsiiniliselt ravitud patsientide abikõlblikud trombolüütiline ravi. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. täiendava teabe jaoks vt osa 5.